GlassScriptPhysician profile
Thomas Nguyen
NPI 1366706673
$568.80
in general payments reported to CMS, 2019-2025
13 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Addiction Medicine (Preventive Medicine) provider received nationally (typical 2025 total: $115).
See the full distribution for Addiction Medicine (Preventive Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $121 · 2023: $24.31 · 2024: $120 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $120.83 | 2022 | |
| Corcept Therapeutics | $107.50 | 2025 | Korlym |
| Ironshore Pharmaceuticals INC. | $54.63 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $49.99 | 2024-2025 | Dyanavel Xr |
| Abbott Laboratories | $42.04 | 2024 | Freestyle Libre 3 |
| Neos Therapeutics, LP | $37.02 | 2025 | Cotempla Xr-Odt |
| Intra-Sana Laboratories | $34.18 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Indivior INC. | $31.37 | 2025 | Sublocade |
| Novo Nordisk INC | $29.79 | 2025 | Wegovy |
| Aytu Biopharma, INC. | $18.06 | 2024 | Karbinal |
| Abbvie INC. | $15.19 | 2025 | |
| Alkermes, INC. | $14.56 | 2025 | Aristada, Lybalvi |
| Currax Pharmaceuticals LLC | $13.64 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.